Skip to content
ChickenStockChickenStock
ResearchSRPT
Sarepta Therapeutics logo

Sarepta Therapeutics (SRPT) stock

NASDAQ

$14.78-2.31%(-0.35)

As of the Nov 17, 2026 close (U.S. Eastern)

Events and reference metrics · 1

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 17, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

98.81x

P/B

1.03x

P/S

0.81x

Find stocks with P/B ≤ 0.9×

Latest earnings

SEC filings

Jul–Sep 2026(FY2026 Q3)

Revenue decreased 4.5% from the same period a year earlier.

Key reported figures come first. Select one to see the same quarter across three years.

See the same quarter across three years →

Filed Nov 5, 2026 · 10-Q · SEC EDGAR

Reported results are from SEC EDGAR filings. Reference information only, not investment advice.

Insider transactions

Recent Form 4 filings grouped by person, date and transaction type.

5 SEC filings
  • Estepan Ian MichaelChief Operating Officer · Sep 4, 2026Shares withheld for taxes24,799 shares · $551K
    Avg. price $22.22177,184 shares held after
  • Rothfuss CristinEVP, General Counsel · Sep 4, 2026Shares withheld for taxes22,025 shares · $489K
    Avg. price $22.22115,519 shares held after
  • Rodino-Klapac LouisePresident, R&D and Tech Ops · Sep 4, 2026Shares withheld for taxes21,423 shares · $476K
    Avg. price $22.22203,900 shares held after
  • Wong Ryan Ho-YanChief Financial Officer · Sep 4, 2026Shares withheld for taxes13,272 shares · $295K
    Avg. price $22.22121,792 shares held after
  • SEVERINO MICHAELChief Executive Officer · Jul 28, 2026Grant or award756,104 shares
    756,104 shares held after

Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.

Recent SEC filings

40 filings

Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.

Company overview

Expand ▾

Sarepta Therapeutics (SRPT) stock information

NASDAQ

Sarepta Therapeutics (SRPT) is listed on NASDAQ. Its market capitalization is about $1.6B. On trailing-twelve-month earnings the P/E ratio is 98.81, and the P/B ratio is 1.03. Return on equity is 1%. These figures are computed in-house from official filings and are reference information only.

Sarepta Therapeutics — frequently asked questions

What is the P/E ratio of Sarepta Therapeutics (SRPT)?
On a trailing-twelve-month basis, SRPT trades at a P/E ratio of 98.81. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of Sarepta Therapeutics?
SRPT has a market capitalization of about $1.6B. The figure moves with the share price and is refreshed each trading day.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.